Sage Therapeutics/SAGE

$12.89

-3.3%
-
1D1W1MYTD1YMAX

About Sage Therapeutics

Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABA receptors, targeting both synaptic and extra synaptic GABA receptors. Its product ZULRESSO (brexanolone) CIV injection is for the treatment of PPD in individuals 15 years old and older. It is also developing a portfolio of other novel compounds that target GABA receptors, including SAGE-324, which is a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing. Its second area of focus for development is novel compounds that target the NMDA receptor.

Ticker

SAGE

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Barry Greene

Employees

487

Headquarters

Cambridge, United States

SAGE Metrics

BasicAdvanced
$801.22M
Market cap
-
P/E ratio
-$9.05
EPS
0.93
Beta
-
Dividend rate
$801.22M
0.92916
$59.99
$10.92
993.79K
10.506
-48.37%
-52.77%
-52.66%
9.267
1.001
1.002
1,024.7%
-0.8%
-57.35%

What the Analysts think about SAGE

Analyst Ratings

Majority rating from 21 analysts.
Hold

Price Targets

Average projection from 16 analysts.
88.6% upside
High $70.00
Low $14.00
$12.89
Current price
$24.31
Average price target

SAGE Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-41.97% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$77.9M
2,785.19%
Net income
$-32.7M
-83.78%
Profit margin
-41.97%
-99.44%

SAGE Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 56.94%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$2.46
-$2.68
-$3.37
-$0.55
-
Expected
-$2.50
-$2.55
-$2.73
-$1.28
-$1.65
Surprise
-1.44%
4.95%
23.42%
-56.94%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Sage Therapeutics stock?

Sage Therapeutics (SAGE) has a market cap of $801.22M as of April 23, 2024.

What is the P/E ratio for Sage Therapeutics stock?

The price to earnings (P/E) ratio for Sage Therapeutics (SAGE) stock is 0 as of April 23, 2024.

Does Sage Therapeutics stock pay dividends?

No, Sage Therapeutics (SAGE) stock does not pay dividends to its shareholders as of April 23, 2024.

When is the next Sage Therapeutics dividend payment date?

Sage Therapeutics (SAGE) stock does not pay dividends to its shareholders.

What is the beta indicator for Sage Therapeutics?

Sage Therapeutics (SAGE) has a beta rating of 0.93. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Sage Therapeutics stock price target?

The target price for Sage Therapeutics (SAGE) stock is $24.31, which is 88.6% above the current price of $12.89. This is an average based on projections from 16 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Sage Therapeutics stock

Buy or sell Sage Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing